Key facts
- This page summarizes Pedro P. Granadillo's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Jul 2025, 16:05.
Pedro P. Granadillo - 18 Jun 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)
- Reporting relationship
- Director
- Issuer ticker
- RCKT
- Reported as of
- 18 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jul 2025, 16:05:44 UTC
- Prior SEC filing
- 20 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Martin Wilson, as attorney-in-fact for Pedro P. Granadillo
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pedro P. Granadillo filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 18 Jul 2025.
Change
- Previous filing in this sequence was filed on 20 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001217544
Primary reporting owner
GRANADILLO PEDRO P
- Relationship
- Director
- Address
- C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
- Signature
- /s/ Martin Wilson, as attorney-in-fact for Pedro P. Granadillo
- Signature date
- 18 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RCKT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 18 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
RCKT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +24,734
- Change %
- +82%
- Price
- $0.000000
- Shares after
- 54,734
- Date
- 18 Jun 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
Footnote F2
Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $70,000. The RSUs will vest in full on June 18, 2026.